CMP
JAZZ icon

Coston McIsaac & Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Coston McIsaac & Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2
Closed – – 869
2025
Q3 		$0 Hold
2
– – ﹤0.01% 821
2025
Q2 		$0 Buy
+2
New +$217 ﹤0.01% 792
2025
Q1 		– Sell
-2
Closed – – 792
2024
Q4 		$0 Hold
2
– – ﹤0.01% 792
2024
Q3 		$0 Buy
+2
New +$219 ﹤0.01% 783

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Coston McIsaac & Partners's JAZZ Position: Q4 2025 in Review

Coston McIsaac & Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 2 shares.

Coston McIsaac & Partners first reported a position in JAZZ in Q3 2024 and held it in 4 quarters. The position peaked at $0 in Q3 2025. 573 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • Coston McIsaac & Partners reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Coston McIsaac & Partners sold 2 Jazz Pharmaceuticals shares in Q4 2025.
  • Coston McIsaac & Partners first reported a position in Jazz Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Coston McIsaac & Partners's Jazz Pharmaceuticals position peaked at $0 in Q3 2025.
  • 573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Coston McIsaac & Partners's 13F filing for Q4 2025, filed 3 Feb 2026.